Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

• US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
• Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
• Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing
  
  

Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research. The start of construction on the company’s first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide.

“Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.”

This expansion reinforces Novartis’ leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new US-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities. 

US Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth joined Novartis leadership, employees, and community partners to celebrate the start of construction. 

“I’m pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.”

The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest US RLT manufacturing network and further builds on the company’s longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical to delivering treatment as planned.

In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company’s broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines. The Denton groundbreaking builds on rapid progress across Novartis’ US investment plan.

• May 2026: Breaking ground on a new RLT manufacturing facility in Denton, Texas, to produce cancer treatments, expanding the company’s coast-to-coast RLT network to five sites (site location previously announced in February 2026)
• April 2026: Announced a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient manufacturing for solid dosage tablets, capsules and RNA therapeutics across oncology, immunology, and cardiovascular, renal and metabolic diseases
• February 2026: Broke ground on a new biomedical research center in San Diego, California, expanding its US research presence alongside Cambridge, Massachusetts, and supporting discovery across disease areas including neuroscience and oncology
• January 2026: Announced a new RLT manufacturing facility for cancer treatments in Winter Park, Florida, the first in the southeastern US
• December 2025: Broke ground on a flagship manufacturing hub in North Carolina, adding solid dosage tablet and capsule and biologics production and sterile packaging for treatments across oncology, immunology, neuroscience, and cardiovascular, renal and metabolic diseases
• November 2025: Opened a new RLT manufacturing facility for cancer treatments in Carlsbad, California – the first such site in the region serving the western US, Alaska, and Hawaii
• Ongoing: Expansions of existing RLT facilities in Indianapolis, Indiana, and Millburn, New Jersey, supporting current and future demand for these cancer treatments

Novartis and radioligand therapy (RLT)
Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells anywhere in the body.  

Novartis is actively investigating the application of RLTs across cancer types and settings, with one of the deepest and most advanced pipelines in the industry, with trials in prostate cancer, breast, colon, lung, brain, pancreatic and other cancers. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites around the world.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; or strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that such products will be commercially successful in the future. Nor can there be any guarantee that the expected benefits from the plans and investments described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Novartis Media Relations E-mail: media.relations@novartis.com

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com